How to Buy
          RIZE

          Medical Cannabis
          and Life Sciences

          UCITS ETF (FLWR)

          Key Documents

            FUND SUMMARY

            The Rize Medical Cannabis and Life Sciences UCITS ETF (FLWR) seeks to invest in companies that potentially stand to benefit from the increased adoption of cannabis as a medicine, with a focus on companies in the biotechnology/pharma and hemp and cannabidiol (CBD) sectors. FLWR seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Foxberry Medical Cannabis & Life Sciences Index.

            KEY INFORMATION

            • AUM ($USD): 16,455,096
            • TER: 0.65%
            • ISIN: IE00BJXRZ273
            • Base Code: FLWR
            • SFDR Classification: Article 8
            • MSCI ESG Rating: BBB

            INVESTMENT CASE

            Medical cannabis has the potential to help millions of people globally. The stigma is coming down, and the cannabis plant is metamorphosing from a vice steeped in political, legal and cultural controversy to a medicine hailed for its remarkable therapeutic applications. Today, the movement is backed by the tailwinds of favourable legislation, social acceptance, medical recognition and pharmaceutical applications. Cannabis-derived pharmaceutical medicines are now available to treat symptoms associated with multiple sclerosis, certain types of cancer and rare forms of childhood epilepsy, including Lennox-Gastaut syndrome and Dravet syndrome. Our purpose-built investment strategy and ETF – Europe’s first truly global medical cannabis ETF – provides investors with access to companies that are positively exposed to the revolution in cannabis-derived medicine. As the medical cannabis movement gathers steam, catalysed by breakthroughs in our understanding of cannabinoids and the corresponding trend towards liberalisation and legalisation, getting on the front foot of this megatrend has its perks for those who can spot the investment opportunity today.

            WHY FLWR?

            • Favourable Growth Prospects

              FLWR is Europe’s first truly global medical cannabis ETF, and provides investors with exposure to the global revolution in cannabis-derived medication and wellness products.

            • Powered by New Frontier Data®

              FLWR is purpose-built in collaboration with New Frontier Data, an independent cannabis research and tech-driven analytics firm based in Washington, D.C., and leverages their unique insights and proprietary classification system of companies that have demonstrable exposure to the emerging medical cannabis and life sciences sector.

            • Unconstrained Approach

              FLWR’s composition transcends classic sector, size and geographic classifications by tracking an emerging theme.

            • ETF Efficiency

              In a single trade, FLWR delivers access to dozens of companies that are favourably positioned to ride the tailwinds of the medical cannabis and life sciences theme.

            Thematic Classification

            FLWR invests in companies within the eligible sub-sectors of the thematic classification for the global cannabis industry built by cannabis industry experts New Frontier Data. The classification is an enabling taxonomy designed for the investment and research communities with the aim of identifying the 7 key sectors within the global cannabis industry – 4 of which are eligible for selection by FLWR – including the eligible companies and business activities that stand to benefit from the increased adoption of cannabis as a medicine.

            View More

            MEDICAL CANNABIS AND LIFE SCIENCES

            Agriculture Technology and Supplies

            Biotechnology/Pharma

            Big Pharma

            Hemp and CBD

            Performance

            CHART (%)
            TABLE (%)
            RIZE MEDICAL CANNABIS AND LIFE SCIENCES UCITS ETF
            Foxberry Medical Cannabis & Life Sciences Index

            Capital at risk. Past performance is not a reliable indicator of future results. The value of your investment and income generated will vary, your initial investment amount cannot be guaranteed. The return of your investment may increase or decrease as a result of currency fluctuations.

            As of
            CumulativeETFIndexTracking Difference
            Year to date
            1 month
            3 months
            6 months
            1 year
            Inception

            Capital at risk. Past performance is not a reliable indicator of future results. The value of your investment and income generated will vary, your initial investment amount cannot be guaranteed. The return of your investment may increase or decrease as a result of currency fluctuations.

            Scroll

            Top 10 Holdings

            NameISINWeightCCY
            REVVITY INCUS714046109315.45USD
            SCOTTS MIRACLE-GRO CLASS’A’COM NPVUS810186106515.33USD
            JAZZ PHARMACEUTICALS PLC COM USD0.0001IE00B4Q5ZN4715.01USD
            PERRIGO COMPANY LIMITED COM EUR0.001IE00BGH1M56814.51USD
            CARA THERAPEUTICS INC COMUS14075510928.61USD
            GROWGENERATION CORP COMUS39986L10988.17USD
            ABBVIE INC COMUS00287Y10915.67USD
            TEVA PHARMACEUTICAL INDS LTD ADRUS88162420985.66USD
            NOVARTIS AG SPONSORED ADRUS66987V10985.49USD
            HYDROFARM HLDGS GROUP INC COM NEWUS44888K20961.54USD

            Full fund holdings

            Scroll

            Fund Details

            Net AssetsUSD 16,455,096
            NAV per shareUSD 2.2428
            Shares Outstanding7,336,994
            Total Expense Ratio0.65
            Inception12/02/2020
            ISINIE00BJXRZ273
            Base CodeFLWR
            Base CurrencyUSD
            Index NameFoxberry Medical Cannabis and Life Sciences Index / FXBYFLWR
            Thematic ClassificationNew Frontier Data Sector Classifications
            Index Replication MethodPhysical – full replication
            Income TreatmentAccumulating
            No. of holdings15
            UCITSYes
            DomicileIreland
            IssuerRize UCITS ICAV
            PromoterRize ETF Limited
            ManagerIQ EQ Fund Management (Ireland) Limited
            Investment ManagerIQ EQ Fund Management (Ireland) Limited
            Depositary / CustodianNorthern Trust Fiduciary Services (Ireland) Limited
            ISA Eligible (UK)Yes
            SIPP Eligible (UK)Yes
            Reporting Fund Status (UK)Yes
            Equity Fund (DE)Yes
            SFDR ClassificationArticle 8

            Scroll

            Registrations

            • Austria
            • Denmark
            • Finland
            • Germany
            • Ireland
            • Italy
            • Luxembourg
            • Netherlands
            • Norway
            • Spain
            • Sweden
            • Switzerland
            • United Kingdom

            Listings

            ExchangeCurrencyListing DateSEDOLBloomberg TickerRIC
            Deutsche Börse XetraEUR17-Feb-20BJXRZL6BLUM GYBLUG.DE
            London Stock ExchangeUSD18-Feb-20BJXRZC7FLWR LNFLWR.L
            London Stock ExchangeGBP18-Feb-20BK5TNN5FLWG LNFLWG.L
            SIX Swiss ExchangeCHF09-Jul-20BJXRZF0FLWR SEFLWR.S

            Scroll

            Research & Insights

            View More

            Fund Documents

            All Other Documents

            Risks

            The Fund is vulnerable to cyclical declines in the cannabis sector.

            Any change to existing applicable laws or regulations that currently enable companies to engage in cannabis-related business activities ("CRB Activities") would reduce the value of affected companies and the Fund.

            Also, some companies may breach such applicable laws or regulations which may (1) cause them to be de-listed from stock exchanges and/or reduce their market value (and therefore reduce the Fund’s value or its ability to realise its investments) and/or (2) mean that capital gains or income derived from such companies cause the Fund and/or the Fund's investors to be in breach of anti-money laundering laws or other laws applicable to them respectively ("Applicable Laws").

            The Fund may have exposure to the recreational consumer market for cannabis even though it does not intend to. This might mean that the capital gains or income derived from companies with this exposure cause the Fund and/or the Fund's investors to be in breach of Applicable Laws.

            A change in any legal requirements relating to funds with cannabis exposure might require the Manager to stop marketing the Fund in certain countries, de-list the Fund’s Shares from certain stock exchanges; and/or close the Fund.

            The Fund invests in pharmaceutical companies which may never generate revenue due to clinical trial failures and/or a lack of required approvals for new drugs. Such factors could severely reduce the values of affected companies and the Fund. The Fund also invests in small publicly traded companies which may be more vulnerable to adverse business or economic events and greater and more unpredictable price changes than larger companies.

            The Fund invests in global equity securities. As such there is a risk of loss arising from exchange rate fluctuations or exchange control regulations.

            Other: (1) Third party service providers (such as the ICAV’s depositary) may go bankrupt and fail to pay money due to the Fund or return property belonging to the Fund. (2) If the Index provider stops calculating the Index or if the Fund’s license to replicate the Index is terminated, the Fund may have to be closed. (3) It may not always be possible to buy and sell the Fund’s Shares on a stock exchange or at prices closely reflecting the Net Asset Value. (4) There is no capital guarantee or protection on the value of the Fund and investors can lose all the capital invested in the Fund. (5) Please refer to the “Risk Factors” section of the ICAV’s Prospectus and the Fund Supplement.

            • 1
            • 2
            • 3

            Select Your Country

            United Kingdom
            Germany
            Italy
            Switzerland
            Austria
            Denmark
            Finland
            Ireland
            Luxembourg
            Netherlands
            Norway
            Spain
            Sweden

            Select Your Investor Type

            ======